AMENDMENT #4 TO: EXCLUSIVE LICENSE BETWEEN KINEMED INC. AND THE REGENTS OF THE UNIVERSITY OF CALIFORNIA FOR ***

Exhibit 10.14

*** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

UNIVERSITY OF CALIFORNIA, BERKELEY

OFFICE OF TECHNOLOGY LICENSING

AMENDMENT #4 TO:

EXCLUSIVE LICENSE

BETWEEN

KINEMED INC.

AND

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

FOR

***

UC Case Nos: ***

UNIVERSITY OF CALIFORNIA, BERKELEY

OFFICE OF TECHNOLOGY LICENSING

AMENDMENT #4 TO:

EXCLUSIVE LICENSE FOR

***

UC Case Nos: ***

Effective November 6, 2003 (the “EFFECTIVE DATE OF AMENDMENT #4”), THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation, whose legal address is 1111 Franklin Street, 12th Floor, Oakland, California ###-###-####, acting through its Office of Technology Licensing, at the University of California, Berkeley, 2150 Shattuck Avenue, Suite 510, Berkeley, CA ###-###-#### (“REGENTS”) and KINEMED, INC., a Delaware corporation having a principal place of business at EmeryStation North, 5980 Horton Street, Suite 470, Emeryville, CA ###-###-#### (“LICENSEE”), agree to amend that certain Agreement between REGENTS and LICENSEE which bears an effective date of February 16, 2001 (as amended previously through Amendments #1, #2, and #3, said Amendments #1, #2, and #3 bearing effective dates of June 15, 2002, October 15, 2002, and March 25, 2003, respectively), as follows:

ARTICLE 1.1 (n) (BACKGROUND) add the following:

1.1 n) ***

1.1 o) ***

*** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

ARTICLE 2.1(j) (DEFINITIONS) substitute the following:

(j) All of Regents' United States patent applications filed under U.C. Case Numbers *** as described in Article 1.1 (c) through (o) above, and;

ARTICLE 5.1(b) (LICENSE ISSUE FEE) substitute the following:

5.1(b) As of the EFFECTIVE DATE OF AMENDMENT #4, REGENTS acknowledges the LICENSEE has fully paid to REGENTS all stock and cash license and amendment fees that were due to REGENTS under the original Agreement and under Amendments #1, #2, and #3 thereto.

As consideration for the addition of REGENTS' cases *** by way of this fourth amendment to the Agreement, LICENSEE shall also pay to REGENTS a non-creditable, non-refundable fee of *** on or before *** and shall, within *** days after the final execution of this amendment #4 to the Agreement, cause to be issued to REGENTS, through its nominee, Shellwater & Co., and to REGENTS employee(s) a total of *** shares of common stock in KineMed, Inc., in accordance with the Shareholder's Agreements between REGENTS and LICENSEE attached hereto as Exhibit A.

ARTICLE 5.1(c) (LICENSE ISSUE FEE) substitute the following:

5.1(c) For any of the following U.C. Case Numbers: *** as described in Article 2.1(j) and in Article 1.1 (c) through (o) above, if the corresponding patent application(s) have not resulted at least one VALID CLAIM, then for each such U.C. Case Number, LICENSEE shall be entitled to a credit of *** toward its future royalty payments to REGENTS pursuant to Article 6.1.

*** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

ARTICLE 7.2 (DUE DILIGENCE) substitute the following

7.2 (c) within *** after the final execution date of this Agreement, LICENSEE shall have ***.

All remaining terms and conditions of the Agreement (as amended) remain in full force and effect.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement in duplicate originals by their duly authorized officers or representatives.

*** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.